A detailed history of Bill & Melinda Gates Foundation transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Bill & Melinda Gates Foundation holds 1,559,142 shares of VIR stock, worth $12.5 Million. This represents 26.84% of its overall portfolio holdings.

Number of Shares
1,559,142
Previous 1,559,142 -0.0%
Holding current value
$12.5 Million
Previous $13.9 Million 15.85%
% of portfolio
26.84%
Previous 34.5%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

BUY
$21.19 - $40.01 $18.7 Million - $35.3 Million
881,365 Added 130.04%
1,559,142 $40.1 Million
Q3 2021

Nov 15, 2021

SELL
$34.9 - $54.54 $73.3 Million - $115 Million
-2,100,000 Reduced 75.6%
677,777 $29.5 Million
Q4 2020

Feb 16, 2021

BUY
$25.51 - $43.38 $70.9 Million - $120 Million
2,777,777 New
2,777,777 $74 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.06B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Bill & Melinda Gates Foundation Portfolio

Follow Bill & Melinda Gates Foundation and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bill & Melinda Gates Foundation, based on Form 13F filings with the SEC.

News

Stay updated on Bill & Melinda Gates Foundation with notifications on news.